Korea’s Celltrion Advances Its First Novel Therapy, Universal Influenza Treatment
This article was originally published in PharmAsia News
Executive Summary
Beyond its main focus of biosimilars, Celltrion is pursuing an influenza therapy that would be its first original product.
You may also be interested in...
Green Cross Obtains South Korean Approval For Peramivir During Drive To Secure More Anti-Influenza Medicines Beyond Roche and GSK Products
SEOUL - South Korea's Green Cross has obtained approval from South Korea's FDA to sell the injectable antiviral drug Rapiacta (peramivir), developed by BioCryst Pharmaceuticals in the U.S., during a government drive to make more flu-fighting medicines available beyond Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir)
Korea FDA Rebuts Reports Of Compulsory Licensing For Roche's Tamiflu
SEOUL - Korea FDA rejected Friday local press reports that the Korean government - jittery over the rising number of local people infected with A/H1N1- will soon exercise the option of "compulsory licensing" to produce generic versions of Roche's Tamiflu (oseltamivir)
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.